Entirety Biomedical

Executive Summary

Entirety Biomedical is a privately held, early-stage medical device company based in Cambridge, MA, founded in 2021. The company is developing Curasorb Alloy, a novel absorbable metal implant technology designed to replace traditional titanium implants in surgical procedures. By matching the mechanical performance and surgical handling of permanent implants while safely resorbing after healing, Curasorb aims to eliminate long-term complications, reduce patient discomfort, and improve post-surgery outcomes. The technology targets applications in oncology and immunology, potentially addressing unmet needs in orthopedic reconstruction, tumor resection, and implant-related immune responses. While still preclinical, Entirety Biomedical's approach could disrupt the $10B+ global orthopedic implant market if validated clinically. However, as a pre-revenue startup with no disclosed funding or partnerships, the company faces significant development and regulatory risks.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement70% success
• Q4 2026First-in-Human Clinical Trial Initiation40% success
• Q2 2026FDA Breakthrough Device Designation50% success